TY - JOUR T1 - Quantitative Prediction of Human Pregnane X Receptor and Cytochrome P450 3A4 Mediated Drug-Drug Interaction in a Novel Multiple Humanized Mouse Line JF - Molecular Pharmacology JO - Mol Pharmacol SP - 518 LP - 528 DO - 10.1124/mol.111.071845 VL - 80 IS - 3 AU - Maki Hasegawa AU - Yury Kapelyukh AU - Harunobu Tahara AU - Jost Seibler AU - Anja Rode AU - Sylvia Krueger AU - Dongtao N. Lee AU - C. Roland Wolf AU - Nico Scheer Y1 - 2011/09/01 UR - http://molpharm.aspetjournals.org/content/80/3/518.abstract N2 - Cytochrome P450 (P450) 3A4 is the predominant P450 enzyme expressed in human liver and intestine, and it is involved in the metabolism of approximately 50% of clinically used drugs. Because of the differences in the multiplicity of CYP3A genes and the poor correlation of substrate specificity of CYP3A proteins between species, the extrapolation of CYP3A-mediated metabolism of a drug from animals to man is difficult. This situation is further complicated by the fact that the predictability of the clinically common drug-drug interaction of pregnane X receptor (PXR)-mediated CYP3A4 induction by animal studies is limited as a result of marked species differences in the interaction of many drugs with this receptor. Here we describe a novel multiple humanized mouse line that combines a humanization for PXR, the closely related constitutive androstane receptor, and a replacement of the mouse Cyp3a cluster with a large human genomic region carrying CYP3A4 and CYP3A7. We provide evidence that this model shows a human-like CYP3A4 induction response to different PXR activators, that it allows the ranking of these activators according to their potency to induce CYP3A4 expression in the human liver, and that it provides an experimental approach to quantitatively predict PXR/CYP3A4-mediated drug-drug interactions in humans. ER -